Probi
ISIN: SE0001280355 | Ticker: PROB | LEI: 5493004CJOCT273MU397
Country: Sweden
Probi is an international company focused exclusively on developing, producing, and delivering clinically proven probiotics. We’ve spent three decades exploring and refining solutions that make the health-enhancing benefits of probiotics available to people everywhere.
We are experts at managing stable, live bacteria from R&D through every stage of the manufacturing process, and into finished products, including bulk formats, supplements, and functional foods. Health concepts, formulations, and formats are supported by documentation.
Since our founding at Sweden’s Lund University, in 1991, Probi has expanded its presence to more than 40 markets. We hold more than 400 patents globally.
1991
Served areaWorldwide
HeadquartersIdeongatan 1A, 22370 Lund – Sweden
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 1,239,893,000.00 | 1,432,169,000.00 | 1,569,888,000.00 |
| Noncurrent Assets | N/A | 830,081,000.00 | 958,586,000.00 | 1,029,591,000.00 |
| Property Plant And Equipment | N/A | 103,076,000.00 | 166,678,000.00 | 212,352,000.00 |
| Buildings | N/A | 939,000.00 | 7,002,000.00 | 19,934,000.00 |
| Machinery | N/A | 17,986,000.00 | 38,899,000.00 | 64,606,000.00 |
| Construction In Progress | N/A | 38,853,000.00 | 38,732,000.00 | 53,267,000.00 |
| Other Property Plant And Equipment | N/A | 2,280,000.00 | 7,306,000.00 | 8,999,000.00 |
| Goodwill | N/A | 278,238,000.00 | 307,011,000.00 | 353,887,000.00 |
| Intangible Assets Under Development | N/A | 39,620,000.00 | 32,096,000.00 | 24,782,000.00 |
| Deferred Tax Assets | N/A | 28,000.00 | 301,000.00 | 357,000.00 |
| Current Assets | N/A | 409,812,000.00 | 473,583,000.00 | 540,297,000.00 |
| Trade And Other Current Receivables | N/A | 95,864,000.00 | 128,744,000.00 | 100,346,000.00 |
| Other Current Receivables | N/A | 2,785,000.00 | 3,705,000.00 | 3,941,000.00 |
| Current Tax Assets Current | N/A | N/A | 0.00 | 781,000.00 |
| Cash and cash equivalents | 206,960,000.00 | 215,552,000.00 | 251,017,000.00 | 323,706,000.00 |
| Other Cash And Cash Equivalents | N/A | 215,552,000.00 | 251,017,000.00 | 323,706,000.00 |
| Current Prepayments And Other Current Assets | N/A | 3,740,000.00 | 5,979,000.00 | 6,329,000.00 |
| Equity And Liabilities | N/A | 1,239,893,000.00 | 1,432,169,000.00 | 1,569,888,000.00 |
| Equity | 1,152,126,000.00 | 1,115,203,000.00 | 1,265,541,000.00 | 1,410,567,000.00 |
| Issued Capital | N/A | 58,221,000.00 | 58,221,000.00 | 58,221,000.00 |
| Retained Earnings | N/A | 514,811,000.00 | 585,422,000.00 | 611,232,000.00 |
| Additional Paidin Capital | N/A | 600,205,000.00 | 600,205,000.00 | 600,205,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 1,115,203,000.00 | 1,265,541,000.00 | 1,410,567,000.00 |
| Noncurrent Liabilities | N/A | 34,874,000.00 | 67,481,000.00 | 59,081,000.00 |
| Deferred Tax Liabilities | N/A | 3,906,000.00 | 13,359,000.00 | 13,833,000.00 |
| Other Noncurrent Liabilities | N/A | 4,299,000.00 | 4,748,000.00 | 5,480,000.00 |
| Current Liabilities | N/A | 85,910,000.00 | 85,788,000.00 | 86,407,000.00 |
| Accruals Classified As Current | N/A | N/A | 18,580,000.00 | 30,150,000.00 |
| Other Current Liabilities | N/A | 4,204,000.00 | 4,496,000.00 | 5,052,000.00 |
| Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue From Interest | 241,000.00 | 154,000.00 | 1,705,000.00 |
| Revenue From Contracts With Customers | 717,165,000.00 | 658,180,000.00 | 618,285,000.00 |
| Profit Loss From Operating Activities | 123,681,000.00 | 109,243,000.00 | 50,574,000.00 |
| Profit Loss Before Tax | 120,087,000.00 | 107,439,000.00 | 51,974,000.00 |
| Income Tax Expense Continuing Operations | 27,394,000.00 | 24,294,000.00 | 11,352,000.00 |
| Profit (loss) | 92,693,000.00 | 83,145,000.00 | 40,622,000.00 |
| Profit Loss Attributable To Owners Of Parent | 92,693,000.00 | 83,145,000.00 | 40,622,000.00 |
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | 92,693,000.00 | 83,145,000.00 | 40,622,000.00 |
| Adjustments For Income Tax Expense | N/A | 27,394,000.00 | 24,294,000.00 | 11,352,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -30,973,000.00 | 13,300,000.00 | -8,936,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 72,780,000.00 | 73,285,000.00 | 85,682,000.00 |
| Other Adjustments For Noncash Items | N/A | 3,419,000.00 | 2,274,000.00 | 4,036,000.00 |
| Cash Flows From Used In Operating Activities | N/A | 143,364,000.00 | 154,195,000.00 | 156,094,000.00 |
| Other Cash Payments To Acquire Equity Or Debt Instruments Of Other Entities Classified As Investing Activities | N/A | 53,032,000.00 | 55,891,000.00 | 0.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | 0.00 | 973,000.00 | 20,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 30,036,000.00 | 35,147,000.00 | 52,429,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 13,334,000.00 | 7,416,000.00 | 12,180,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -96,402,000.00 | -97,481,000.00 | -64,589,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 241,000.00 | 154,000.00 | 1,705,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 13,146,000.00 | 12,418,000.00 | 13,743,000.00 |
| Dividends Paid Classified As Financing Activities | N/A | 11,394,000.00 | 12,534,000.00 | 14,812,000.00 |
| Interest Paid Classified As Financing Activities | N/A | 3,388,000.00 | 3,190,000.00 | 2,458,000.00 |
| Cash Flows From Used In Financing Activities | N/A | -27,687,000.00 | -27,988,000.00 | -29,308,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 19,275,000.00 | 28,726,000.00 | 62,197,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -10,683,000.00 | 6,739,000.00 | 10,492,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 8,592,000.00 | 35,465,000.00 | 72,689,000.00 |
| Cash and cash equivalents | 206,960,000.00 | 215,552,000.00 | 251,017,000.00 | 323,706,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 06.05.22 | Henrik Lundkvist | Other | Buy | SEK 27,981.00 |
| 29.04.22 | Tom Rönnlund | Other | Buy | SEK 122,296.00 |
| 28.04.22 | Tom Rönnlund | Other | Buy | SEK 287,015.70 |
| 06.05.20 | Tom Rönnlund | Other | Buy | SEK 100,000.00 |
SE0001280355
LEI5493004CJOCT273MU397
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.